Analysis of drug use in institutionalized individuals with intellectual disability and tube feeding

References

• Balogh R, Ouellette-Kuntz H, Bourne L, Lunsky Y, Colantonio A. Organising health care services for persons with an intellectual disability. Cochrane Database of Syst Rev. 2008;4; 1-39.
   Google Scholar
• Jansen DEMC, Krol B, Groothoff JW, Post D. People with intellectual disability and their health problems: a review of comparative studies. J Intellect Disability Res. 2004;48:93–102.10.1111/jir.2004.48.issue-2
   PubMed Web of Science ®Google Scholar
• Jauhari P, Bhargava R, Bhave A, Kumar C, Kumar R. Comorbidities associated with intellectual disability among pediatric outpatients seen at a teaching hospital in Northern India. J Policy Pract Intellect Disabilities. 2012;9(1):10–16.10.1111/jppi.2012.9.issue-1
   Web of Science ®Google Scholar
• Gal E, Hardal-Nasser R, Engel-Yeger B. The relationship between the severity of eating problems and intellectual developmental deficit level. Res Dev Disabilities. 2011;32(5):1464–9.10.1016/j.ridd.2010.12.003
   PubMed Web of Science ®Google Scholar
• White R, Bradnam V. Handbook of drug administration via enteral feeding tubes. 2nd revised ed. London: Pharmaceutical Press; 2011.
   Google Scholar
• Bankhead R, Boullata J, Brantley S, Corkins M, Guenter P, Krenitsky J, et al. A.S.P.E.N. Enteral nutrition practice recommendations. J Parenter Enteral Nutr. 2009;33(2):122–67.10.1177/0148607108330314
   PubMedGoogle Scholar
• WHO collaboration centre for drug statistics methodology. 2013 Available from: http://www.whocc.no/atc_ddd_index/.
   Google Scholar
• ABDATA Pharma-Daten-Service. Werbe- und vertriebsgesellschaft deutscher apotheker mbH. Eschborn, Germany; 2005.
   Google Scholar
• Baxter K, and Preston, C., Ed. Stockley’s drug interactions. 10th ed. London: Parmaceutical Press; 2013.
   Google Scholar
• Lexi-Interact. UpToDate, Inc.; 2014 Available from: http://www.uptodate.com/contents/drug-interaction.
   Google Scholar
• CredibleMeds.org. AZCERT, Inc.; 2014 Available from: http://crediblemeds.org/everyone/composite-list-all-qtdrugs/?rf=All.
   Google Scholar
• American Society of Hospital Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993;50(2):305–14.
   PubMedGoogle Scholar
• Wallace J, Paauw DS. Appropriate prescribing and important drug interactions in older adults. Med Clin North Am. 2015;99(2):295–310.10.1016/j.mcna.2014.11.005
   PubMed Web of Science ®Google Scholar
• Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533–44.10.1586/17512433.2014.910111
   PubMed Web of Science ®Google Scholar
• Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489–97.10.1002/pds.v23.5
   PubMed Web of Science ®Google Scholar
• Cornu P, Steurbaut S, Šoštarić S, Mrhar A, Dupont AG. Performance of a clinical decision support system and of clinical pharmacists in preventing drug-drug interactions on a geriatric ward. Int J Clin Pharm. 2014;36(3):519–25.10.1007/s11096-014-9925-x
   PubMed Web of Science ®Google Scholar
• Lea M, Rognan SE, Koristovic R, Wyller TB, Molden E. Severity and management of drug-drug interactions in acute geriatric patients. Drugs Aging. 2013;30(9):721–7.
   PubMed Web of Science ®Google Scholar
• Salvi F, Marchetti A, D’Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a cause of hospitalization in older adults. Drug Safety. 2012;35:29–45.10.1007/BF03319101
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–16.10.1001/jama.289.9.1107
   PubMed Web of Science ®Google Scholar
• van der Heide DC, van der Putten AAJ, van den Berg PB, Taxis K, Vlaskamp C. The documentation of health problems in relation to prescribed medication in people with profound intellectual and multiple disabilities. J Intellect Disability Res. 2009;53:161–8.10.1111/jir.2009.53.issue-2
   PubMed Web of Science ®Google Scholar
• Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 2000;41(2):107–39.10.1016/S0920-1211(00)00124-8
   PubMed Web of Science ®Google Scholar
• Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)—Part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52(11):927–66.10.1007/s40262-013-0087-0
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473–481.10.1016/S1474-4422(03)00483-6
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347–56.10.1016/S1474-4422(03)00409-5
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–55.10.1111/bcp.2006.61.issue-3
   PubMed Web of Science ®Google Scholar
• Schier JG, Howland MA, Hoffman RS, Nelson LS. Fatality from administration of labetalol and crushed extended-release nifedipine. Ann Pharmacother. 2003;37(10):1420–23.10.1345/aph.1D091
   PubMed Web of Science ®Google Scholar
• Joos E, Mehuys E, Van Bocxlaer J, et al. Medication Management in Belgian Residential Care Facilities for Individuals With Intellectual Disability: An Observational Study. Journal of Policy and Practice in Intellectual Disabilities 2014;11:27–33.
   Web of Science ®Google Scholar